| Description | STX-478 is an orally active and selective PI3Kα inhibitor that penetrates the blood-brain barrier and has anticancer activity to inhibit tumor growth.STX-478 is indicated for the study of breast cancer and other cancers. |
| In vitro | STX - 478( 0-10 000 n M;1h)靶向 MCF10A 细胞(具有 H1047R 激酶结构域突变)[1]。 |
| In vivo | 在 Female BALB/c 裸鼠（CAL-33异种移植模型）中，STX-478（30, 100 mg/kg；口服给药）显示出剂量依赖性地减少肿瘤体积的效果[1]。 |
| molecular weight | 401.29 |
| Molecular formula | C16H12F5N5O2 |
| CAS | 2883540-92-7 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 100 mg/mL (249.20 mM), Sonication is recommended. |
| References | 1. JR David St Jean, et al. Urea derivatives which can be used to treat cancer. Patent WO2022265993A1. |